Colorectal
The following list provides a brief description of colorectal cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
DYNAMIC -Rectal
| Registered Title | Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study (DYNAMIC-RECTAL) |
| Purpose | The primary purpose of this study is to show that by using ctDNA results, in addition to assessing the risk of tumour recurrence by standard pathology assessments, the number of patients receiving adjuvant (post surgery) chemotherapy will be reduced. |
| Lay Summary | It is hoped that the findings from this study will demonstrate that using ctDNA results to help make a decision as to who receives adjuvant chemotherapy will result in a reduction in the number of patients having chemotherapy and doing so, without compromising the rate of disease recurrence when compared to standard of care. |
| WA Trial Sites |  Cancer Centre Clinical Trials Unit Ph. 08 615 26530 |
| Links | Australian New Zealand Clinical Trials Registry |
Acknowledgements: Australian New Zealand Clinical Trials Registry
CA224-020
| Registered Title | A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors |
| Purpose | The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. |
| Lay Summary | N/A |
| WA Trial Sites |  Linear Clinical Research Ph. 08 6382 5513 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
ARCS-Multi (BAY 94-9343)
| Registered Title | Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies |
| Purpose | The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. |
| Lay Summary | N/A |
| WA Trial Sites | Ph. 08 615 26530 |
| Links | Australian New Zealand Clinical Trials Registry |
Acknowledgements: Australian New Zealand Clinical Trials Registry
ASCOLT Study
|
Registered Title |
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial. |
|
Purpose |
We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally.. |
|
Lay Summary |
N/A |
|
WA Trial Sites |
|
|
Links |
Acknowledgements: US National Library of Medicine
DYNAMIC III
| Registered Title |
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study |
| Purpose | The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer. |
| Lay Summary | Who is it for? You may be eligible to join this study if you are aged 18 years or more and have undergone curative surgery for stage III colon cancer. Study details All patients will be followed up every 3 months for 2 years, then every 6 months for 3 years in order to evaluate treatment safety and efficacy. Follow-up involves additional blood tests and radiological assessments. It is hoped that the findings from this study will demonstrate that using ctDNA results to help make a decision regarding adjuvant chemotherapy is not inferior to standard of care in terms of recurrence-free survival. |
| WA Trial Sites |
|
| Links | Australian New Zealand Clinical Trials Registry |
Acknowledgements: Australian New Zealand Clinical Trials Registry
[Return to List of Clinical Trials]
